HPV vaccination for adults

CDC experts reviewed 16 published reports, along with unpublished evidence, before updating 2014 guidelines on HPV vaccination last year to address adult immunizations. As part of the process, members of the Advisory Committee on Immunization Practices considered who should receive catch-up vaccination through age 26 years.

CDC experts reviewed 16 published reports, along with unpublished evidence, before updating 2014 guidelines on HPV vaccination last year to address adult immunizations. As part of the process, members of the Advisory Committee on Immunization Practices considered who should receive catch-up vaccination through age 26 years. They also contemplated which individuals older than that would benefit from the vaccine, which is safe and highly effective but not cost-effective on a universal basis in older populations. While the earlier iteration recommended vaccination for all males aged 13–21 years and catch-up vaccination through age 26 years for all women, MSM, transgender persons, and anyone with a compromised immune system, the new version simplifies the guidance by including all males and females aged 21–26 years. As for the second question, the update offers a system of selective vaccination for those aged 27–45 years. In particular, the vaccine may most beneficial for people in that age range who have had few intimate partners and are at greater risk of getting HPV from new ones. However, clinicians are directed to engage in shared decision-making with their patients based on their individual risk/benefit profile.